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The crystal structure of pirfenidone, C12H11NO [alternative name: 5-methyl-1-
phenylpyridin-2(1H)-one], an active pharmaceutical ingredient (API) approved
in Europe and Japan for the treatment of Idiopathic pulmonary fibrosis (IPF), is
reported here for the first time. It was crystallized from toluene by the
temperature gradient technique, and crystallizes in the chiral monoclinic space
group P21. The phenyl and pyridone rings are inclined to each other by
50.30 (11). In the crystal, molecules are linked by C–H  O hydrogen bonds
involving the same acceptor atom, forming undulating layers lying parallel to the
ab plane.
1. Chemical context
Idiopathic Pulmonary Fibrosis (IPF) is a lung disease char-
acterized by cough, scars and dyspnea that leads to progressive
and irreversible loss of lung function. Pirfenidone (systematic
name: 5-methyl-1-phenyl-1H-pyridin-2-one) has been
approved in Japan since 2008 (Pirespa1) and in Europe since
2011 (Esbriet1) for the treatment of IPF, even if its
mechanism of action has not been completely elucidated
(Richeldi et al., 2011). Different synthetic approaches have
been reported, mainly relying on N-arylation reactions of
5-methyl-2-pyridone (Liu et al., 2009; Crifar et al., 2014; Jung et
al., 2016; Falb et al., 2017). Pirfenidone has been known since
1974 (Gadekar, 1974) and its antifibrotic properties were
described in 1990 (Margolin, 1990). Nevertheless, despite its
formulation as oral tablets, no information on the solid-state
structure of this compound has been reported to date. In the




The molecular structure of pirfenidone is shown in Fig. 1. This
axially chiral molecule crystallizes in the monoclinic space
group P21, with one molecule in a general position. The
molecule is far from planar with the phenyl (C7–C12) and
pyridinone (N1/C1–C5) rings subtending a dihedral angle of
50.30 (11).
3. Supramolecular features
In the crystal, molecules are linked by C—H  O hydrogen
bonds involving the same acceptor atom (Table 1), forming an
undulating network, enclosing R34(20) ring motifs, and lying
parallel to the ab plane (Figs. 2 and 3). The R34(20) ring motifs
are clearly visible in Fig. 3. There are no other significant
intermolecular contacts present according to the analysis of
the crystal structure using PLATON (Spek, 2009).
4. Database Survey
A search of the Cambridge Structural Database (CSD,
Version 5.40, February 2019; Groom et al., 2016) for
1-phenylpyridin-2(1H)-ones, excluding structures with ring
atoms being included in further cyclic moieties, gave 40 hits
(see supporting information file S1). Only six of these
compounds involve an unsubstituted phenyl ring as in the title
compound. When considering compounds with no substituent
in position-6 of the pyridinone ring (on atom C5 in the title
compound; Fig. 1) only three structures fit this extra criteria,
viz. S-ethyl 2-oxo-1-phenyl-1,2-dihydro-3-pyridinecarbothio-
ate (CSD refcode NOLBIA; Liu et al., 2008), monoclinic space
group P21, 4-chloro-6-oxo-1-phenyl-1,6-dihydropyridine-3-
carbaldehyde (QIWFIM; Xiang et al., 2008), monoclinic space
group P21/c, and methyl 5-benzoyl-2-oxo-1-phenyl-1,2-di-
hydropyridine-4-carboxylate (TEMKIH; Shao et al., 2012),
orthorhombic space group Pna21 with two independent mol-
ecules in the asymmetric unit. In these three compounds, the
phenyl ring is inclined to the pyridone ring by ca 65.50, 64.66
and 55.83/57.12, respectively. This dihedral angle in the title
compound, pirfenidone, is 50.30 (11). In the other three
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Table 1
Hydrogen-bond geometry (A˚, ).
D—H  A D—H H  A D  A D—H  A
C8—H8  O1i 0.93 2.33 3.203 (3) 156
C10—H10  O1ii 0.93 2.46 3.310 (3) 152
Symmetry codes: (i) x  1; y; z; (ii) xþ 2; y 12;zþ 2.
Figure 2
A view along the a axis of the crystal packing of pirfenidone. The C—
H  O hydrogen bonds (see Table 1) are shown as dashed lines.
Figure 3
A view along the c axis of the crystal packing of pirfenidone. The C—
H  O hydrogen bonds (see Table 1) are shown as dashed lines.
Figure 1
Aview of the molecular structure of pirfenidone with the atom labelling.
Displacement ellipsoids are drawn at the 50% probability level.
compounds [AQIKIV (Gorobets et al., 2010), BAFPUV
(Dyachenko et al., 2011) and WEDCEP (Allais et al., 2012) –
see supporting information file S1] with a substituent in
position-6 of the pyridinone ring the corresponding dihedral
angle varies from ca 73.02 to 89.28 as a result of steric
hindrance.
5. Synthesis and crystallization
Pirfenidone was obtained in > 99.5% purity according to the
method published previously (Mossotti et al., 2018). Single
crystals were grown in the following way: approximately
100 mg of pirfenidone in 2 mL of toluene was heated until
complete dissolution. The flask with this solution was then
closed and kept at 273–278 K. Well-formed colourless crystals
of pirfenidone were obtained after 1 week. The melting point
of this crystal form, determined by DSC analysis (heating rate
10 K min1), is 383 K. This crystallization procedure must be
performed in order to grow single crystals suitable for X-ray
diffraction analysis and not with the aim of increasing the
purity of the product. It is worth nothing that the industrial
process is already optimized for the isolation of a pure API
(> 99.5%) and a further crystallization step is not needed to
improve its purity. We performed several other crystallization
trials in order to search for other possible forms of pirfeni-
done; however, each crystallization attempt gave rise to the
same crystal form.
6. Refinement
Crystal data, data collection and structure refinement details
are summarized in Table 2. The H atoms were included in
calculated positions and treated as riding: C—H = 0.93–0.96 A˚
with Uiso(H) = 1.5Ueq(C-methyl) and 1.2Ueq(C) for other H
atoms.
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Crystal system, space group Monoclinic, P21
Temperature (K) 293
a, b, c (A˚) 6.2525 (8), 7.797 (1), 10.2810 (13)
 () 104.744 (2)
V (A˚3) 484.70 (11)
Z 2
Radiation type Mo K
 (mm1) 0.08
Crystal size (mm) 0.50  0.45  0.05
Data collection
Diffractometer Bruker SMART APEX CCD
Absorption correction Multi-scan (SADABS; Bruker,
2010)
Tmin, Tmax 0.692, 0.746
No. of measured, independent and






R[F 2 > 2(F 2)], wR(F 2), S 0.037, 0.095, 1.04
No. of reflections 2128
No. of parameters 127
No. of restraints 1
H-atom treatment H-atom parameters constrained
max, min (e A˚
3) 0.11, 0.20
Absolute structure Flack x determined using 762
quotients [(I+)(I)]/[(I+)+(I)]
(Parsons et al., 2013)
Absolute structure parameter 0.3 (4)
Computer programs: APEX2 and SAINT (Bruker, 2010), SHELXT2017 (Sheldrick,
2015a), SHELXL2017 (Sheldrick, 2015b), ORTEP-3 for Windows (Farrugia, 2012),
Mercury (Macrae et al., 2008), PLATON (Spek, 2009) and publCIF (Westrip, 2010).
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Computing details 
Data collection: APEX2 (Bruker, 2010); cell refinement: SAINT (Bruker, 2010); data reduction: SAINT (Bruker, 2010); 
program(s) used to solve structure: SHELXT2017 (Sheldrick, 2015a); program(s) used to refine structure: SHELXL2017 
(Sheldrick, 2015b); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012) and Mercury (Macrae et al., 2008); 







a = 6.2525 (8) Å
b = 7.797 (1) Å
c = 10.2810 (13) Å
β = 104.744 (2)°
V = 484.70 (11) Å3
Z = 2
F(000) = 196
Dx = 1.269 Mg m−3
Melting point: 375 K
Mo Kα radiation, λ = 0.71073 Å
Cell parameters from 2547 reflections
θ = 3.3–27.2°
µ = 0.08 mm−1
T = 293 K
Plate, colourless
0.50 × 0.45 × 0.05 mm
Data collection 
Bruker SMART APEX CCD 
diffractometer
ω scans
Absorption correction: multi-scan 
(SADABS; Bruker, 2010)
Tmin = 0.692, Tmax = 0.746
4547 measured reflections
2128 independent reflections
1879 reflections with I > 2σ(I)
Rint = 0.019













Hydrogen site location: inferred from 
neighbouring sites
H-atom parameters constrained
w = 1/[σ2(Fo2) + (0.0528P)2 + 0.0476P] 
where P = (Fo2 + 2Fc2)/3
(Δ/σ)max < 0.001
supporting information
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Δρmax = 0.11 e Å−3
Δρmin = −0.20 e Å−3
Absolute structure: Flack x determined using 
762 quotients [(I+)-(I-)]/[(I+)+(I-)] (Parsons et al., 
2013)
Absolute structure parameter: 0.3 (4)
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance 
matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; 
correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate 
(isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. none
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
x y z Uiso*/Ueq
N1 0.7599 (2) 0.5275 (2) 0.62509 (16) 0.0382 (4)
O1 1.0951 (2) 0.6634 (3) 0.69330 (17) 0.0602 (5)
C1 0.9386 (3) 0.6188 (3) 0.6002 (2) 0.0437 (5)
C5 0.5769 (3) 0.4849 (3) 0.5233 (2) 0.0395 (5)
H5 0.460421 0.428046 0.545647 0.047*
C7 0.7635 (3) 0.4782 (3) 0.76141 (19) 0.0401 (5)
C4 0.5595 (3) 0.5219 (3) 0.3929 (2) 0.0430 (5)
C12 0.9445 (4) 0.3913 (3) 0.8390 (2) 0.0497 (5)
H12 1.066616 0.368712 0.805687 0.060*
C8 0.5830 (3) 0.5134 (3) 0.8108 (2) 0.0481 (5)
H8 0.462114 0.572084 0.758231 0.058*
C6 0.3599 (4) 0.4732 (3) 0.2835 (2) 0.0579 (6)
H6A 0.400128 0.387266 0.227127 0.087*
H6B 0.304346 0.572565 0.230447 0.087*
H6C 0.247695 0.428652 0.322817 0.087*
C11 0.9409 (5) 0.3383 (3) 0.9672 (2) 0.0616 (7)
H11 1.061057 0.278817 1.019737 0.074*
C3 0.7416 (4) 0.6079 (3) 0.3637 (2) 0.0527 (6)
H3 0.737708 0.633055 0.274701 0.063*
C2 0.9189 (4) 0.6537 (3) 0.4608 (2) 0.0540 (6)
H2 1.033979 0.710617 0.436893 0.065*
C9 0.5836 (4) 0.4604 (4) 0.9395 (2) 0.0623 (7)
H9 0.462501 0.484254 0.973553 0.075*
C10 0.7616 (5) 0.3728 (4) 1.0174 (2) 0.0649 (7)
H10 0.760634 0.337171 1.103577 0.078*
Atomic displacement parameters (Å2) 
U11 U22 U33 U12 U13 U23
N1 0.0355 (8) 0.0426 (9) 0.0362 (8) 0.0009 (8) 0.0084 (7) 0.0007 (7)
O1 0.0399 (8) 0.0725 (11) 0.0631 (11) −0.0111 (8) 0.0038 (7) −0.0046 (9)
C1 0.0368 (10) 0.0430 (12) 0.0524 (12) 0.0007 (9) 0.0134 (9) −0.0023 (10)
C5 0.0380 (9) 0.0395 (11) 0.0398 (10) −0.0026 (9) 0.0078 (8) 0.0011 (9)
C7 0.0411 (10) 0.0397 (11) 0.0362 (10) −0.0013 (8) 0.0034 (8) 0.0002 (8)
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C4 0.0524 (11) 0.0376 (11) 0.0376 (10) −0.0009 (10) 0.0087 (9) −0.0001 (9)
C12 0.0496 (12) 0.0478 (12) 0.0459 (12) 0.0081 (10) 0.0017 (10) −0.0051 (10)
C8 0.0395 (10) 0.0602 (13) 0.0435 (11) −0.0003 (10) 0.0082 (8) 0.0070 (11)
C6 0.0705 (15) 0.0570 (15) 0.0399 (11) −0.0077 (13) 0.0026 (11) −0.0004 (11)
C11 0.0708 (16) 0.0522 (14) 0.0469 (13) 0.0053 (12) −0.0126 (12) 0.0046 (11)
C3 0.0694 (15) 0.0522 (14) 0.0410 (11) −0.0091 (11) 0.0224 (11) 0.0002 (10)
C2 0.0559 (13) 0.0556 (14) 0.0576 (14) −0.0113 (12) 0.0276 (11) −0.0015 (11)
C9 0.0595 (14) 0.0851 (19) 0.0450 (13) −0.0110 (13) 0.0183 (11) 0.0036 (13)
C10 0.0826 (19) 0.0688 (17) 0.0378 (12) −0.0134 (16) 0.0054 (12) 0.0103 (12)
Geometric parameters (Å, º) 
N1—C5 1.381 (2) C8—C9 1.386 (3)
N1—C1 1.402 (2) C8—H8 0.9300
N1—C7 1.448 (3) C6—H6A 0.9600
O1—C1 1.232 (3) C6—H6B 0.9600
C1—C2 1.432 (3) C6—H6C 0.9600
C5—C4 1.349 (3) C11—C10 1.375 (4)
C5—H5 0.9300 C11—H11 0.9300
C7—C8 1.378 (3) C3—C2 1.338 (3)
C7—C12 1.384 (3) C3—H3 0.9300
C4—C3 1.417 (3) C2—H2 0.9300
C4—C6 1.501 (3) C9—C10 1.376 (4)
C12—C11 1.386 (4) C9—H9 0.9300
C12—H12 0.9300 C10—H10 0.9300
C5—N1—C1 121.93 (17) C4—C6—H6A 109.5
C5—N1—C7 118.39 (16) C4—C6—H6B 109.5
C1—N1—C7 119.67 (16) H6A—C6—H6B 109.5
O1—C1—N1 120.88 (19) C4—C6—H6C 109.5
O1—C1—C2 124.9 (2) H6A—C6—H6C 109.5
N1—C1—C2 114.20 (18) H6B—C6—H6C 109.5
C4—C5—N1 122.94 (19) C10—C11—C12 120.7 (2)
C4—C5—H5 118.5 C10—C11—H11 119.7
N1—C5—H5 118.5 C12—C11—H11 119.7
C8—C7—C12 120.74 (19) C2—C3—C4 121.7 (2)
C8—C7—N1 119.42 (17) C2—C3—H3 119.1
C12—C7—N1 119.81 (19) C4—C3—H3 119.1
C5—C4—C3 116.47 (19) C3—C2—C1 122.6 (2)
C5—C4—C6 122.2 (2) C3—C2—H2 118.7
C3—C4—C6 121.4 (2) C1—C2—H2 118.7
C7—C12—C11 119.0 (2) C10—C9—C8 120.6 (2)
C7—C12—H12 120.5 C10—C9—H9 119.7
C11—C12—H12 120.5 C8—C9—H9 119.7
C7—C8—C9 119.3 (2) C11—C10—C9 119.7 (2)
C7—C8—H8 120.4 C11—C10—H10 120.2
C9—C8—H8 120.4 C9—C10—H10 120.2
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Hydrogen-bond geometry (Å, º) 
D—H···A D—H H···A D···A D—H···A
C8—H8···O1i 0.93 2.33 3.203 (3) 156
C10—H10···O1ii 0.93 2.46 3.310 (3) 152
Symmetry codes: (i) x−1, y, z; (ii) −x+2, y−1/2, −z+2.
